Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2116 to 2130 of 9029 results

  1. Serplulimab with pemetrexed and carboplatin for untreated EGFR and ALK mutation-negative advanced non-squamous non-small-cell lung cancer [GID-TA12039]

    Awaiting development Reference number: GID-TA12039 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Serplulimab with carboplatin and nab-paclitaxel for untreated advanced squamous non-small cell lung cancer [GID-TA12040]

    Awaiting development Reference number: GID-TA12040 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Serplulimab with chemotherapy for untreated PD-L1-positive unresectable advanced or recurrent oesophageal squamous cell cancer [GID-TA12038]

    Awaiting development Reference number: GID-TA12038 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Asundexian for preventing stroke after acute non-cardioembolic ischaemic stroke or high-risk transient ischaemic attack [GID-TA12033]

    Awaiting development Reference number: GID-TA12033 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Giredestrant for adjuvant treatment of oestrogen-receptor positive HER2-negative early breast cancer [GID-TA12031

    Awaiting development Reference number: GID-TA12031 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]

    Awaiting development Reference number: GID-TA11198 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma [TSID10736]

    Awaiting development Reference number: GID-TA11076 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Ianalumab for treating active Sjogren's syndrome ID6634: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 4 June 2026.

    Technology appraisal guidance
    In consultation

  9. Ianalumab for treating active Sjogren's syndrome ID6634

    In development Reference number: GID-TA11836 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA779) [ID6326]

    In development Reference number: GID-TA11764 Expected publication date:  23 July 2026

    Technology appraisal guidance
    In development

  11. Middle meningeal artery embolisation for chronic subdural haematomas

    In development Reference number: GID-IPG10440 Expected publication date:  19 November 2026

    Interventional procedures guidance
    In development

  12. Extravascular implantable cardioverter defibrillator insertion for preventing sudden cardiac death caused by ventricular arrhythmia

    In development Reference number: GID-IPG10437 Expected publication date:  08 April 2027

    Interventional procedures guidance
    In development

  13. In-situ normothermic regional perfusion of the abdomen for livers donated after controlled circulatory death

    In development Reference number: GID-IPG10405 Expected publication date:  19 November 2026

    Interventional procedures guidance
    In development

  14. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 therapies (MA review TA704 and TA862) [ID5121]

    In development Reference number: GID-TA11674 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Fenebrutinib for treating relapsing multiple sclerosis [ID6577]

    Awaiting development Reference number: GID-TA11775 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development